健康元：健康元药业集团股份有限公司2021年半年度报告（英文版）.PDF

《健康元：健康元药业集团股份有限公司2021年半年度报告（英文版）.PDF》由会员分享，可在线阅读，更多相关《健康元：健康元药业集团股份有限公司2021年半年度报告（英文版）.PDF（217页珍藏版）》请在得力文库 - 分享文档赚钱的网站上搜索。

1、 1 IMPORTANT NOTICE I The Board of Directors (the Board), the Supervisory Committee and the Directors, Supervisors and senior management of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of this interim report (the Report), and that there are no false represen

2、tations, misleading statements or material omissions contained in the Report, and severally and jointly accept responsibility. II All the Directors of the Company attended the board meeting. III The interim financial report of the Company is unaudited. IV Mr. Zhu Baoguo (朱 保 国), the person-in-charge

3、 of the Company, and Mr. Qiu Qingfeng (邱 庆 丰), the person-in-charge of the Companys accounting work and the person-in-charge of the accounting department (the head of the accounting department), declare that they hereby warrant the truthfulness, accuracy and completeness of the financial statements

4、contained in the Report. V Profit distribution plan or plan for conversion of capital reserve to share capital approved by the Board during the Reporting Period Not applicable VI Risk declaration for the forward-looking statementsApplicable N/AThe Report contains forward-looking statements which inv

5、olve the future plans, development strategies, etc. of the Company, yet do not constitute substantive undertakings of the Company to investors. Investors should exercise caution prior to making investment decisions. VII Whether there is non-operating use of funds by the controlling shareholder and t

6、heir related parties ?No VIII Whether there is a violation of the prescribed decision-making procedures to provide external guarantees ?No IX Whether more than half of the Directors cannot warrant the truthfulness, accuracy and completeness of the Report disclosed by the Company ?No X Significant ri

7、sk warningsThere is no exceptionally significant risk that will have a material impact on the productions and operations of the Company during the Reporting Period. The Company has described various risks related to productions and operations that the Company may face and the corresponding response

8、measures taken. Please refer to Risks in Chapter 3 Management Discussion and Analysis. XI OthersApplicable N/A XII The Report is prepared in both Chinese and English. In case of any ambiguity in the understanding of the Chinese and English texts, the Chinese version shall prevail. 2 Financial Highli

9、ghts .3Chapter 1 Definitions .5Chapter 2 Company Profile and Major Financial Indicators .7Chapter 3 Management Discussion and Analysis .10Chapter 4 Corporate Governance .31Chapter 5 Environmental and Social Responsibility .34Chapter 6 Major Events .57Chapter 7 Changes in Equity and Shareholders .67C

10、hapter 8 Informatoin on Preferred Shares .70Chapter 9 Information on Bonds .71Chapter 10 Financial Report .72List of documents available for inspectionThe Financial Statements signed and sealed by the person-in-charge of the Company, the person-in-charge of the Companys accounting work and the perso

11、n-in-charge of the accounting department (the head of the accounting department)The original copies of all documents and announcements of the Company which have been disclosed to the public on the website designated by CSRC during the Reporting PeriodTable of Contents 3 Financial Highlights0.34680.3

12、504Major Financial Indicators（RMB in 100 million）EPS（RMB /Share）EPS-diluted（RMB /Share）Composition of Principal Businesses (RMB in 100 million)64.76 78.35 RevenuesNet profit Total profitattributable toshareholders ofthe CompanyNet profit afterextraordinary profitand loss attributableto shareholders

13、ofthe Company0.34830.35140.89%0.80%0.6256.97%44.348.13%6.3329.02%22.595.02%3.91Chemical drug preparation products APIs and Intermediates Diagnostic reagentsand equipmentTraditional Chinese drugpreparation products Health Care productsTotal Income Of Principal Businesses77.846.76 5.92 6.87 5.98 Same

14、PeriodLast YearReporting Period1.04%21.00%1.64%0.94% 4 9,84012,94015,691153,1305,7646,9317,5269,75111,75320,29953,5462,601 3,662 9,019 8,05611,381Income from Sales of Key Products During the Reporting Period(RMB in 10,000) and YOY ChangeBudesonide Suspension for InhalationLevosalbutamolHydrochloride

15、 NebuliserSolutionCompound Ipratropium Bromide Solution for InhalationNew1743.09%134.45%30,77881,782LeuprorelinAcetate Microspheres forInjectionUrofollitropinfor Injection52.49%70.14%11,51045,621Meropenemfor injectionVoriconazolefor Injection-1.15%9.00%IlaprazoleSeriesRabeprazoleSodium Enteric-coate

16、d CapsulesLivzonWeisanlianLivzonDele130.64%65.67%27.48%Fluvoxamine Maleate TabletsPerospironeHydrochlorideTablets40.67%77.21%22,80029,903Shenqi FuzhengInjectionAnti-viral Granules11.27%-24.57%7-ACA(+D-7ACA)MeropenemTrihydrate12.93%48.96%PhenylalanineDaptomycinVancomycinHydrochlorideMevastatinAcarbos

17、eLincomycin14.37%17.62%90.40%15.07%142.34%-38.89%Drug preparation products:Inhalation制剂产品：抗感染APIs and intermediates-9.92%Drug preparation products:psychiatryDrug preparation products:GastroenterologyDrug preparation products:traditional Chinese drug preparationDrug preparation products:Anti-infectiv

18、eDrug preparation products:gonadotropic hormones27,187 5 In this Report, unless the context otherwise requires, the following expressions shall have the following meanings:Definitions of common termsCSRCRefers toChina Securities Regulatory CommissionBaiyeyuan or the Controlling ShareholderRefers toS

19、henzhen Baiyeyuan Investment Co., Ltd. * (深圳市百业源投资有限公司)Company or the CompanyRefers toJoincare Pharmaceutical Group Industry Co., Ltd. * (健康元药业集团股份有限公司)GMPRefers toGood Manufacturing PracticeGSPRefers toGood Supply PracticeBERefers toBioequivalence Livzon GroupRefers toLivzon Pharmaceutical Group In

20、c.* (丽珠医药集团股份有限公司)Haibin PharmaRefers toShenzhen Haibin Pharmaceutical Co., Ltd.* (深圳市海滨制药有限公司)Xinxiang Haibin Refers toXinxiang Haibin Pharmaceutical Co., Ltd. * (新乡海滨药业有限公司)Taitai Pharmaceutical Refers toShenzhen Taitai Pharmaceutical Co., Ltd. * (深圳太太药业有限公司)Taitai GenomicsRefers toShenzhen Taitai

21、 Genomics Inc.Co.,Ltd. * (深圳太太基因工程有限公司)Joincare Biopharmaceutical Research Institute Refers toHenan Province Joincare Biopharmaceutical Research Institute Co., Ltd. * (河南省健康元生物医药研究院有限公司)Jiaozuo Joincare Refers toJiaozuo Joincare Bio Technological Co., Ltd.(焦作健康元生物制品有限公司)Joincare Daily-Use Refers toJ

22、oincare Daily-Use & Health Care Co., Ltd. * (健康元日用保健品有限公司)Topsino Refers toTopsino Industries Limited * (天诚实业有限公司)Fenglei Electric PowerRefers toShenzhen Fenglei Electric Power Investment Co., Ltd. * (深圳市风雷电力投资有限公司)Zhuhai JiankangyuanRefers toZhuhai Jiankangyuan Biology Medicine Co.,Ltd. * (珠海健康元生物医

23、药有限公司)Health Pharmaceutical Refers toHealth Pharmaceutical (China) Co., Ltd. * (健康药业(中国)有限公司)Hiyeah IndustryRefers toShenzhen Hiyeah Industry Co., Ltd. * (深圳市喜悦实业有限公司)Shanghai FrontierRefers toShanghai Frontier Health Pharmaceutical Technology Co., Ltd. * (上海方予健康医药科技有限公司)Joincare Special Medicine Fo

24、odRefers toJoincare (Guangdong) Special Medicine Food Co., Ltd. * (健康元(广东)特医食品有限公司)Joincare BVIRefers toJoincare Pharmaceutical Group Industry Co., LtdLivzon MABRefers toLivzon MABPharm Inc. * (珠海市丽珠单抗生物技术有限公司)Livzon DiagnosticsRefers toZhuhai Livzon Diagnostics Inc. * (珠海丽珠试剂股份有限公司)Fuzhou FuxingRef

25、ers toLivzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd.* (丽珠集团福州福兴医药有限公司)Xinbeijiang Pharmaceutical Refers toLivzon Group Xinbeijiang Pharmaceutical Manufacturing Inc.* (丽珠集团新北江制药股份有限公司)Ningxia Pharmaceutical Refers toLivzon Group (Ningxia) Pharmaceutical Manufacturing Co., Ltd.* (丽珠集团(宁夏)制药有限公司)G

26、utian FuxingRefers toGutian Fuxing Pharmaceutical Co., Ltd. * (古田福兴医药有限公司)Livzon HechengRefers toZhuhai FTZ Livzon Hecheng Pharmaceutical Manufacturing Co., Ltd. * (珠海保税区丽珠合成制药有限公司)Livzon Limin Refers toLivzon Group Limin Pharmaceutical Manufacturing Factory * (丽珠集团利民制药厂)Livzon Pharmaceutical Factor

27、y Refers toLivzon Group Livzon Pharmaceutical Factory * (丽珠集团丽珠制药厂)Chapter 1 Definitions 6 Definitions of common termsShanghai Livzon Refers toShanghai Livzon Pharmaceutical Manufacturing Co., Ltd. * (上海丽珠制药有限公司)Sichuan GuangdaRefers toSichuan Guangda Pharmaceutical Manufacturing Co., Ltd. * (四川光大制药

28、有限公司)Jinguan Electric PowerRefers toJiaozuo Jinguan Jiahua Electric Power Co., Ltd. * (焦作金冠嘉华电力有限公司)Tianjin TaslyRefers toTianjin Tasly Healthcare Industry Investment Partnership (Limited Partnership)* (天津天士力健康产业投资合伙企业(有限合伙)Tianjin TongrentangRefers toTianjin Tongrentang Group Co., Ltd. * (天津同仁堂集团股份

29、有限公司)Sanmed BiotechRefers toZhuhai Sanmed Biotech Inc. * (珠海圣美生物诊断技术有限公司)Livzon Biologics or Livzon CaymanRefers toLivzon Biologics LimitedLivzon InternationalRefers toLivzon International LimitedYFRefers toYF Pharmab LimitedKadi BiotechnologyRefers toZhuhai Kadi Medical Biotechnology Inc. * (珠海市卡迪生

30、物医药有限公司)Lisheng JuyuanRefers toHainan Lisheng Juyuan Investment Partnership (Limited Partnership) * (海南丽生聚源投资合伙企业(有限合伙)Livzon HKRefers toLivzon Biologics Hong Kong Limited * (丽珠生物科技香港有限公司)LivzonBioRefers toZhuhai Livzon Biotechnology Co., Ltd.* (珠海市丽珠生物医药科技有限公司)COVID-19Refers toa new coronavirus (SA

31、RS-CoV-2)COVID-19 pandemic or pandemicRefers tothe outbreak of the disease caused by a new coronavirus called SARS-CoV-2Ruihua Certified Public AccountantsRefers toRuihua Certified Public Accountants (Special General Partnership)Grant Thornton Refers toGrant Thornton (Special General Partnership)Rep

32、orting PeriodRefers toFrom 1 January 2021 to 30 June 2021End of the Reporting PeriodRefers to30 June 2021Currency or unitRefers toRMB unless otherwise specified*For identification purpose only 7 I Company informationChinese name of the Company健康元药业集团股份有限公司Abbreviation of the Chinese name健康元English n

33、ame of the CompanyJoincare Pharmaceutical Group Industry Co., Ltd.Abbreviation of the English nameJoincareLegal representative of the CompanyZhu Baoguo II Contact persons and contact detailsBoard Secretary Representative of Securities Affairs NameZhao Fengguang (赵凤光)Zhou Xian (周鲜)AddressJoincare Pha

34、rmaceutical Group Building, No. 17, Langshan Road, North District, Hi-tech Zone, Nanshan District, ShenzhenJoincare Pharmaceutical Group Building, No. 17, Langshan Road, North District, Hi-tech Zone, Nanshan District, ShenzhenTelephone0755-86252656, 0755-862523880755-86252656, 0755-86252388Fax0755-8

35、62521650755-86252165E- III Introduction of changes in basic information on the CompanyRegistered address of the CompanyJoincare Pharmaceutical Group Building, No. 17, Langshan Road, North District, Hi-tech Zone, Nanshan District, ShenzhenHistorical changes of registered address of the CompanyRegiste

36、red at B5, Hengfeng Industrial City, Hezhou Community, Huangtian Village, Xinan Town, Baoan County on 18 December 1992Changed its registered address to 4-5/F, Dongpeng Building, Shangmeilin Industrial Area, Futian District, Shenzhen on 25 May 1994Changed its registered address to 24/F, Block B, Fuji

37、an Building, Caitian South Road, Futian District, Shenzhen on 4 July 1995Changed its registered address to 23/F, Diwang Building, Shun Hing Square, No. 333, Shennan East Road, Shenzhen on 20 June 1997Changed its registered address to Taitai Pharmaceutical Industrial Building, the 5th Industrial Area

38、, Nanshan District, Shenzhen on 22 September 2000Changed its registered address to 23/F, Diwang Building, Shun Hing Square, No. 5002, Shennan East Road, Luohu District, Shenzhen on 4 June 2003Changed its registered address to Joincare Pharmaceutical Group Building, No. 17, Langshan Road, North Distr

39、ict, Hi-tech Zone, Nanshan District, Shenzhen on 29 January 2008Changed its registered address to Joincare Pharmaceutical Group Building, No. 17, Langshan Road, North District, Hi-tech Zone, Nanshan District, Shenzhen on 27 November 2012Office address of the CompanyJoincare Pharmaceutical Group Buil

40、ding, No. 17, Langshan Road, North District, Hi-tech Zone, Nanshan District, ShenzhenPostal code of office address of the Company518057Website of the Companyhttp:/E-Index for query of changes during the Reporting PeriodThere was no change during the Reporting PeriodChapter 2 Company Profile and Majo

41、r Financial Indicators 8 IV Introduction of changes in information disclosure and places for inspectionName of designated newspapers for information disclosure by the CompanyChina Securities Journal, Securities Times, Securities Daily, and Shanghai Securities NewsWebsite for publication of interim r

42、eporthttp:/Place for inspection of interim report of the CompanyOffice address of the Company and Shanghai Stock ExchangeIndex for query of changes during the Reporting PeriodThere was no change during the Reporting Period V Company stock profileClass of stockListed onStock abbreviationStock codeSto

43、ck abbreviation prior to changeA ShareShanghai Stock Exchange健康元600380太太药业、S健康元 VI Other relevant informationApplicable N/A VII Principal accounting data and financial indicators of the Company (I) Principal accounting dataUnit: Yuan Currency: RMBPrincipal Accounting DataReporting Period(From Januar

44、y to June)Same Period Last YearYear-on-Year Change (%)Revenues7,835,372,274.666,475,702,905.4021.00Net profit attributable to Shareholders of the listed company687,347,494.53676,265,223.831.64Net profit attributable to Shareholders of the listed company after deducting the extraordinary gain or loss

45、597,892,327.43592,320,636.900.94Net cash flow from operating activities745,787,513.361,248,991,736.51-40.29End of the Reporting PeriodEnd of the Previous YearChange during the Period (%)Net assets attributable to Shareholders of the listed company11,358,911,818.2811,096,125,890.512.37Total assets28,

46、588,683,586.6228,156,977,599.071.53 (II) Principal financial indicatorsPrincipal financial indicatorsReporting Period(From January to June)Same Period Last YearYear-on-Year Change (%)Basic earnings per share (RMB/share)0.35140.34830.89Diluted earnings per share (RMB/share)0.35040.34681.04Basic earni

47、ngs per share after deducting the extraordinary gain or loss (RMB/share)0.30570.30500.23Weighted average return on net assets (%)6.046.34Decreased by 0.3 percentage pointWeighted average return on net assets after deducting the extraordinary gain or loss (%)5.265.56Decreased by 0.3 percentage pointD

48、escription of principal accounting data and financial indicators of the CompanyApplicable N/AThe net cash flow from operating activities was RMB746 million, representing a year-on-year decrease of 40.29%. This was mainly due to the expansion of the specialized sales force and the increase of the inv

49、estment in R&D of biologics and the platform of inhalation preparations during the Reporting Period. 9 Interim Report 2021 VIII Differences in accounting data under domestic and foreign accounting standardsApplicable N/A IX Items and amounts of extraordinary gains and lossesApplicable N/AUnit: Yuan

50、Currency: RMB Items of Extraordinary Gains and Losses AmountsNotes (If applicable)Gains and losses on disposal of non-current assets20,350,801.14Proceeds from disposal of fixed assetsGovernment grants included in profit and loss for the Period (except for government grants closely associated with no